To clarify the clinical implication of preheparin serum lipoprotein lipase
mass (preheparin LpL mass), we studied the relationships between preheparin
LpL mass and serum lipids, including midband lipoproteins, which migrate b
etween very low density lipoproteins and low density lipoproteins on polyac
rylamide gel disc electrophoresis, in hyperlipidemias. And we also studied
the changes of preheparin LpL mass in hypertriglyceridemic patients during
bezafibrate administration, which is known to enhance LDL activity in posth
eparin plasma. Preheparin LpL mass correlated positively with high-density
lipoprotein-cholesterol (HDL-C) (r = 0.418, P < 0.01) and negatively with t
riglyceride (TG) (r = -0.256, P < 0.01), but did not correlate with total c
holesterol (TC) in 64 hyperlipidemic (type IIa, IIb and IV) patients. The m
idband lipoproteins were observed in 80% of hypertriglyceridemic patients (
32/40). Preheparin LpL mass in midband lipoprotein-positive subjects was lo
wer significantly than that in midband-negative subjects. When bezafibrate
(400 mg/day) was administrated to 40 hypertriglyceridemic patients for 4 mo
nths, TG level significantly decreased (-49 +/- 7%, P < 0.01), TC levels de
creased (-11 +/- 4%, not significant), and HDL-C levels increased (+27 +/-
4%, P < 0.01). The midband lipoproteins disappeared in 95% of patients. Pre
heparin LpL mass significantly increased (+25 +/- 6%, P < 0.0005). In nine
patients who stopped bezafibrate, TG levels significantly increased (+49 +/
- 7%, P < 0.01) and HDL-C levels decreased (-27 +/- 4%, P < 0.01). Prehepar
in LPL mass significantly decreased (-25 +/- 6%, P < 0.0005). These results
suggested that bezafibrate administration enhanced preheparin LpL mass. An
d it might be implicated that enhanced LpL production by bezafibrate could
reflect an increase of preheparin LpL mass. (C) 2000 Elsevier Science Irela
nd Ltd. All rights reserved.